Last reviewed · How we verify
Trans-catheter embolization
Trans-catheter embolization is a Small molecule drug developed by Shenzhen SiBiono GeneTech Co.,Ltd. It is currently in Phase 2 development.
Trans-catheter embolization is a medical intervention used to treat conditions such as venous insufficiency, hepatocellular carcinoma, and varicosities, typically involving the embolization of incompetent veins. This procedure can be performed using various agents, including Lipiodol, T-ACE Oil, and embolotherapy of incompetent gonadal and iliac veins.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Trans-catheter embolization |
|---|---|
| Sponsor | Shenzhen SiBiono GeneTech Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma (PHASE1, PHASE2)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial (NA)
- Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients (PHASE4)
- TAE and Surgery in Patients With Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy (NA)
- Effectiveness of Drug Eluting TACE in Primary HCC (EARLY_PHASE1)
- The Effectiveness of Trans-catheter Foam Sclerotherapy of Pelvic and Atypical Lower Limb Varicosities (NA)
- Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trans-catheter embolization CI brief — competitive landscape report
- Trans-catheter embolization updates RSS · CI watch RSS
- Shenzhen SiBiono GeneTech Co.,Ltd portfolio CI
Frequently asked questions about Trans-catheter embolization
What is Trans-catheter embolization?
Who makes Trans-catheter embolization?
What development phase is Trans-catheter embolization in?
Related
- Manufacturer: Shenzhen SiBiono GeneTech Co.,Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing